US FDA inspection delay at Monroe plant
The Monroe facility is awaiting FDA inspection, delaying potential revenue from injectable products. Management has limited visibility on timing.
high · management_commentary
Glenmark Pharmaceuticals Limited — Q3 FY25
Glenmark delivered a strong Q3 FY25 with consolidated revenue of INR 3,388 crore, up 35.1% YoY, driven by a 300% surge in India formulation sales to INR 1,064 crore, aided by ne...
bullish
high
✓ Verified against BSE filing
Risk Intelligence
Material risks this quarter
Concise cards keep the risk register scannable while preserving evidence-level context in the underlying quarter data.
Risks
Currency headwinds in emerging markets
Adverse currency movements in LATAM, South Africa, and Russia impacted reported growth and EBITDA margins by approximately INR 71 crore in Q3.
medium · management_commentaryIndia business slowdown in acute respiratory
Q3 India formulation growth was impacted by a slowdown in acute respiratory sales, though management expects recovery in Q4.
medium · analyst_questionCompetition in GLP-1 market
The Indian GLP-1 market is expected to become crowded, potentially limiting Glenmark's market share despite its first-mover advantage with Lirafit.
medium · analyst_question